RBC Capital Reiterates Buy Rating on VRDN
RBC Capital maintains its buy rating on VRDN with a price target of $35, a 86.27% upside from the current price.
Key Points
- RBC Capital reiterated its buy rating for VRDN with a $35 price target on June 30, 2026.
- RBC Capital's $35 price target implies 86.27% upside from Viridian Therapeutics, Inc.'s ($VRDN) current $18.79 share price.
- Shares of VRDN traded near $18.79 on Tuesday.
- Major institutions like BlackRock and State Street have increased their holdings in VRDN.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
RBC Capital maintained its buy rating on VRDN, setting a price target of $35 on June 30, 2026. This comes as the stock traded near $18.79 on Tuesday.
RBC Capital vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in VRDN
Several major institutional investors have been active in VRDN. FMR LLC increased its holdings by 994,921 shares, bringing its total to 15,379,377 shares valued at approximately $300.8 million, marking a 6.9% increase. BlackRock, Inc. added 1,399,552 shares, a 21.8% increase, to hold 7,831,475 shares worth about $153.2 million. Bellevue Group AG significantly lifted its stake by 2,367,617 shares, a 54.3% increase, resulting in 6,726,144 shares valued at around $131.6 million. State Street Corp grew its position by 1,206,325 shares, a 34.8% increase, totaling 4,672,885 shares valued at $91.4 million. Meanwhile, Vanguard Capital Management LLC opened a new position with 4,167,201 shares valued at approximately $81.5 million.
Viridian Therapeutics, Inc. Stock Down 18.6%
Shares of VRDN traded near $18.79 on Tuesday. The stock has been drawing attention from several institutional investors, as reflected in their recent activity.
$VRDN price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Viridian Therapeutics, Inc.
Fairmount Funds Management LLC bought 1,176,470 shares at an average price of $17.00 on May 11, 2026. Jennifer Tousignant, Chief Legal Officer, sold 1,675 shares at an average price of $30.19 on March 3, 2026, while also purchasing 5,169 shares on the same day. Other insiders, including Thomas Beetham, Chief Operating Officer, and Seth Harmon, Chief Financial Officer, sold shares on March 3, 2026.
Analysts Set New Price Targets
On June 30, 2026, RBC Capital reiterated its buy rating with a $35 price target. Truist Securities also maintained a buy rating, setting a target of $38. Wedbush kept its buy rating with a $43 target, and Needham maintained its buy rating with a $34 target. Wells Fargo upgraded the stock to a buy with a $31 target on June 29, 2026.
Bottom Line
RBC Capital's reiteration of its buy rating for VRDN with a $35 target highlights continued confidence in the stock. Institutional interest, with significant increases in holdings by major investors like BlackRock and State Street, supports this outlook. These updates provide insights for investors tracking VRDN's performance and analyst perspectives.
Get Viridian Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $VRDN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.